Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant ...

The full manuscript, titled “Enozertinib is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-small Cell Lung Cancer with EGFR Exon 20 and Atypical Mutations,” is available online at Cancer ...

ORIC Pharmaceuticals announces scientific details of discovery and development of enozertinib: South San Francisco Saturday, November 8, 2025, 13:00 Hrs [IST] ORIC Pharmaceuticals ...

Weakened lung function diagnosis can potentially be achieved sooner in the aging process with increased monitoring.

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 15 stocks set to explode in 2026. On November 7, 2025, Summit ...

In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung ...

OptiTROP-Lung04 study showed sac-TMT improved survival in pts with EGFR-mutated NSCLC who had progressed on EGFR-targeted TKIs, compared with chemotherapy.

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms ...